Cozaar 50mg tablets

国: イギリス

言語: 英語

ソース: MHRA (Medicines & Healthcare Products Regulatory Agency)

有効成分:

Losartan potassium

から入手可能:

Dowelhurst Ltd

ATCコード:

C09CA01

INN（国際名）:

Losartan potassium

投薬量:

50mg

医薬品形態:

Oral tablet

投与経路:

Oral

クラス:

No Controlled Drug Status

処方タイプ:

Valid as a prescribable product

製品概要:

BNF: 02050502

情報リーフレット

PACKAGE LEAFLET: INFORMATION FOR THE USER
COZAAR
® 50MG TABLETS
(losartan potassium)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START
TAKING THIS MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor,
pharmacist or nurse.

This medicine has been prescribed for you only. Do
not pass it on to others. It may harm them, even if
their signs of illness are the same as yours.

If you get any side effects, talk to your doctor,
pharmacist, or nurse. This includes any possible
side effects not listed in this leaflet. See section 4.
The name of your medicine is Cozaar 50mg tablets but
will be referred to as Cozaar throughout this leaflet.
Please note that this leaflet also contains information
about other strengths Cozaar 12.5mg, 25mg and
100mg tablets.
WHAT IS IN THIS LEAFLET
1.
What Cozaar is and what it is used for
2.
What you need to know before you take Cozaar
3.
How to take Cozaar
4.
Possible side effects
5.
How to store Cozaar
6.
Contents of the pack and other information
Losartan (Cozaar) belongs to a group of medicines
known as angiotensin-II receptor antagonists.
Angiotensin-II is a substance produced in the body
which binds to receptors in blood vessels, causing them
to tighten. This results in an increase in blood pressure.
Losartan prevents the binding of angiotensin-II to these
receptors, causing the blood vessels to relax which in
turn lowers the blood pressure. Losartan slows the
decrease of kidney function in patients with high blood
pressure and type 2 diabetes.
Cozaar is used

to treat patients with high blood pressure
(hypertension) in adults and in children and
adolescents 6 - 18 years of age.

to protect the kidney in hypertensive type 2 diabetic
patients with laboratory evidence of impaired renal
function and proteinuria ≥ 0.5 g per day (a condition
in which urine contains an abnormal amount of
protein).

to treat patients with chronic heart failure when
therapy with